TGase activity measurement in food preparations

We measure activity in your transglutaminase samples!

Transglutaminase (Microbial transglutaminase, MTG) is a processing aid widely used to improve meat, fish, bakery, and dairy products. Transglutaminase crosslinking can modulate the physical and textural properties of various protein-containing foods.

Transglutaminase Activity:
At Zedira we determine the activity of your transglutaminase sample on a fee for service base.

How to get your sample measured at Zedira?

  1. Sample shipment
    Send us at least 50 g of your sample using a carrier of your choice.
    Ship it to: Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany.
    Please inform us via e-mail about your shipment ( and provide expected activity range.
    Samples typically are MTG concentrates (2,000 – 3,000 U/g) or ready to use MTG formulations (60 – 200 U/g).

  2. Sample measurement
    Transglutaminase activity of your samples is measured using the standard hydroxamate assay (see assay principle below).
    Two independent measurements, in triplicates each, are performed per sample.
    Our internal quality standards require maximal inter-assay and intra-assay deviations of 5%

  3. Results
    Transglutaminase activity of each sample is stated in a Certificate of Analysis (example for download).
    Certificate of analysis is sent to you via e-mail within 1-2 working days after receipt of your sample

  4. Fee for service
    The assay fee per sample is 250 €.
    When sending 3 samples at the same time, fee per analysis is reduced to 225 €.
    The invoice is sent by e-mail and can be paid by bank transfer or credit card.

Please contact us for further questions.

Phone: +49 6151 3251-00

The transglutaminase activity assay principle:
The Standard Hydroxamate Assay uses Z-Gln-Gly-OH as peptidic glutamine substrate and hydroxylamine as amine donor.
In the presence of MTG, hydroxylamine is enzymatically incorporated into the peptide to form Z-glutamyl-hydroxamate-glycine. The hydroxamate forms a red colored complex with iron (III) ions, which is quantified at 525 nm.
One unit of microbial transglutaminase activity is defined as the amount of enzyme, which causes the formation of 1.0 μmole of hydroxamate per minute at 37ºC (Folk and Cole, 1966).

(FAQ - Determination of MTG activity.pdf)


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA